Trial Profile
A Phase II Clinical Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 18 Oct 2023
Price :
$35
*
At a glance
- Drugs Amcasertib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Sponsors Boston Biomedical; Sumitomo Pharma America; Sumitomo Pharma Oncology
- 25 Mar 2019 Status changed from active, no longer recruiting to discontinued due to low feasibility
- 30 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 25 Mar 2017 Status changed from not yet recruiting to recruiting.